Assembly Biosciences, Inc. ASMB
23.25 USD +0.75 (+3.31%)
As ofNov 18, 2026, 9:47 AM EST
22.07 Day range 23.50
19.20 52-week range 39.71
- YTD
- -31.65%
- 1 year
- -35.23%
News
seekingalpha.com Assembly Biosciences, Inc. (ASMB) Presents at UBS Global Biopharma Conference 2026 Transcript Assembly Biosciences, Inc. ( ASMB ) UBS Global Biopharma Conference 2026 November 17, 2026 7:00 AM EST Company Participants Jason Okazaki - CEO, President & Director Anuj Gaggar - Chief Medical…
zacks.com Assembly Biosciences (ASMB) Reports Q3 Loss, Lags Revenue Estimates Assembly Biosciences (ASMB) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to a loss of $0.72 per share a year ago.
globenewswire.com Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates – Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection –benzinga.com UBS Maintains Buy on Assembly Biosciences, Lowers Price Target to $48 UBS analyst Ashwani Verma maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and lowers the price target from $52 to $48.
benzinga.com Assembly Biosciences Doses First Two Patients In Its Phase 2 Clinical Trial Of ABI-6250 To Treat Chronic Hepatitis Delta Virus Infection Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced dosing of the first two participants…
